<rss version="2.0"><channel><title><![CDATA[RSS Feed]]></title><link>http://www.ispe.org</link><description><![CDATA[]]></description><image><link>http://www.ispe.org</link><title>RSS Feed</title><url></url></image><lastBuildDate>Fri, 24 May 2013 17:47:07 -0400</lastBuildDate><language>en</language><item><title><![CDATA[A Comparison of Process Validation Standards]]></title><link><![CDATA[http://www.ispe.org/index.php/ci_id/42543]]></link><guid>42543</guid><pubDate>May 8, 2013</pubDate><description><![CDATA[This article presents a comparison between the Global Harmonization Task Force (GHTF) validation standard and the US Food and Drug Administration’s (FDA’s) process validation guidance.]]></description></item>
<item><title><![CDATA[Classified Advertising with Advertiser’s Index]]></title><link><![CDATA[http://www.ispe.org/index.php/ci_id/42553]]></link><guid>42553</guid><pubDate>May 8, 2013</pubDate><description><![CDATA[]]></description></item>
<item><title><![CDATA[Commissioning and Qualification (Verification) in the Pharmaceutical Product Process Lifecycle]]></title><link><![CDATA[http://www.ispe.org/index.php/ci_id/42542]]></link><guid>42542</guid><pubDate>May 8, 2013</pubDate><description><![CDATA[This article discusses the role of Commissioning and Qualification as “Stage 2a” of the Process Validation Lifecycle described in the US FDA’s Guidance on Process Validation. It also explains how the concepts of Quality Risk Management and QbD are incorporated into facility and system verification efforts as detailed by two recently published ISPE Guides.]]></description></item>
<item><title><![CDATA[Establishing and Managing a Vendor Network for Clinical Supply Manufacturing Services]]></title><link><![CDATA[http://www.ispe.org/index.php/ci_id/42537]]></link><guid>42537</guid><pubDate>May 8, 2013</pubDate><description><![CDATA[This article presents some essential operational and evaluation aspects of the Request for Information/Request for Proposal (RFI/RFP) process when conducted for the purpose of establishing a vendor network for clinical supply manufacturing services.]]></description></item>
<item><title><![CDATA[Effective Computerized System Compliance through Leveraging Supplier Effort]]></title><link><![CDATA[http://www.ispe.org/index.php/ci_id/42541]]></link><guid>42541</guid><pubDate>May 8, 2013</pubDate><description><![CDATA[This article describes a controls framework that can be used to assess risks and determine a validation strategy that leverages supplier effort appropriately.]]></description></item>
<item><title><![CDATA[ISPE Update]]></title><link><![CDATA[http://www.ispe.org/index.php/ci_id/42552]]></link><guid>42552</guid><pubDate>May 8, 2013</pubDate><description><![CDATA[- Second ISPE-FDA Event Attracts Top Names, Features Release of Drug Shortage Survey Results<br>
- ISPE Releases New Guidance for Standardizing Use of Booklet Labels in Global Clinical Trials<br>
- ISPE Releases New Guidance for Definition and Use of NIMPs in Clinical Trials]]></description></item>
<item><title><![CDATA[Pharmaceutical Engineering Interviews]]></title><link><![CDATA[http://www.ispe.org/index.php/ci_id/42538]]></link><guid>42538</guid><pubDate>May 8, 2013</pubDate><description><![CDATA[Roger Nosal, Vice President, Global Chemistry, Manufacturing and Controls (GCMC), Pfizer]]></description></item>
<item><title><![CDATA[Facility of the Future: Next Generation Manufacturing Forum Part III: Identifying Facility Requirements Based on Specific Business Drivers and Uncertainties Using the Enabling Technologies]]></title><link><![CDATA[http://www.ispe.org/index.php/ci_id/42540]]></link><guid>42540</guid><pubDate>May 8, 2013</pubDate><description><![CDATA[This article is the third of a three-part series focused on defining the facility of the future required for manufacturing biopharmaceuticals in the 21st Century.]]></description></item>
<item><title><![CDATA[ISPE Members Making an Impact on Industry Issues Worldwide]]></title><link><![CDATA[http://www.ispe.org/index.php/ci_id/42545]]></link><guid>42545</guid><pubDate>May 8, 2013</pubDate><description><![CDATA[ISPE President and CEO Nancy Berg discusses the impact that ISPE’s new direction is making on individual Members, the companies they work for and regulatory and industry relationships around the world.]]></description></item>
<item><title><![CDATA[Global Regulatory News]]></title><link><![CDATA[http://www.ispe.org/index.php/ci_id/42544]]></link><guid>42544</guid><pubDate>May 8, 2013</pubDate><description><![CDATA[]]></description></item></channel></rss>